What are the indications, recommended dosing, contraindications, and common adverse effects of linaclotide for adults with irritable bowel syndrome with constipation or chronic idiopathic constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Linaclotide

Linaclotide is strongly recommended for adults with chronic idiopathic constipation (CIC) who fail over-the-counter agents and for irritable bowel syndrome with constipation (IBS-C), with FDA-approved dosing of 72-145 mcg daily for CIC and 290 mcg daily for IBS-C, taken on an empty stomach at least 30 minutes before the first meal. 1, 2

Indications

Linaclotide is FDA-approved for:

  • Irritable bowel syndrome with constipation (IBS-C) in adults
  • Chronic idiopathic constipation (CIC) in adults
  • Functional constipation (FC) in pediatric patients 6-17 years of age 2

The 2023 AGA-ACG guidelines provide a strong recommendation for linaclotide use in adults with CIC who do not respond to OTC agents, based on moderate certainty of evidence 1.

Recommended Dosing

Adults:

  • IBS-C: 290 mcg orally once daily 2
  • CIC: 145 mcg orally once daily (standard dose)
    • 72 mcg once daily may be used based on individual presentation or tolerability 2

Pediatric (6-17 years):

  • Functional constipation: 72 mcg orally once daily 2

Administration Instructions:

  • Take on an empty stomach, at least 30 minutes before the first meal, at approximately the same time each day 2
  • Swallow capsule whole; do not crush or chew 2
  • For patients unable to swallow: capsules can be opened and mixed with applesauce or water, or administered via nasogastric/gastrostomy tube 2

Mechanism of Action

Linaclotide is a guanylate cyclase-C agonist that increases cyclic guanosine monophosphate concentrations, resulting in luminal chloride and bicarbonate secretion. This increases intestinal fluid and accelerates GI transit 1. Importantly, it also improves abdominal symptoms of bloating, discomfort, and pain—particularly valuable in IBS-C where these symptoms are prominent 1.

Efficacy

The evidence demonstrates robust efficacy with high certainty for key outcomes:

For CIC:

  • Increases complete spontaneous bowel movements (CSBMs) per week by 1.37 (95% CI 1.07-1.95) 1
  • Increases spontaneous bowel movements (SBMs) per week by 1.97 (95% CI 1.59-2.36) 1
  • Improves stool consistency (MD 1.25,95% CI 1.1-1.39) 1
  • Increases global relief rates (RR 1.96,95% CI 1.63-2.35) 1
  • Responder rates increase 3-fold compared to placebo (RR 3.14,95% CI 1.68-5.88) 1

For IBS-C:

  • Significantly improves both abdominal pain (≥30% reduction) and bowel symptoms 3, 4
  • In a predominantly Chinese population study, 60% of linaclotide patients met abdominal pain/discomfort responder criteria vs 48.8% placebo (P<0.05) 4
  • 31.7% achieved IBS degree of relief vs 15.4% placebo (P<0.0001) 4

The overall certainty of evidence for linaclotide is moderate, with high certainty specifically for bowel movement frequency, stool form, and global relief outcomes 1.

Contraindications

Linaclotide is absolutely contraindicated in:

  • Patients less than 2 years of age (BLACK BOX WARNING: risk of serious dehydration and death) 2
  • Patients with known or suspected mechanical GI obstruction 1

Common Adverse Effects

Diarrhea (Most Common):

  • Occurs in 9-20% of patients in clinical trials 5, 4
  • 3 times more likely than placebo (RR 3.35,95% CI 2.09-5.36) 1
  • Majority (90.5%) is mild to moderate 5
  • Discontinuation due to diarrhea: 4.0-4.7% of patients (vs 0.3% placebo) 1
  • Rate decreases over time: 1.1 events per patient-year in initial trials, dropping to 0.3 in long-term studies 5

Other Adverse Events:

  • Serious adverse events are rare and similar to placebo 5
  • No serious adverse events of diarrhea reported 5
  • Overall discontinuation rates due to any adverse event: 6.9% (vs 3.0% placebo) 1

Important Clinical Considerations

Duration of Treatment:

  • Clinical trials evaluated 12-week treatment periods, but the drug label does not provide a time limit for use 1
  • Long-term safety data available up to 104 weeks show maintained safety profile 5

Special Populations:

  • Elderly (≥65 years): No clear differences in outcomes, though sample sizes were limited 1
  • Can be used as replacement or adjunct to OTC agents 1

Real-World Discontinuation:

The most common reasons for discontinuation over the first year are loss of efficacy and insurance coverage barriers—not adverse events 1. This is a critical practical consideration when counseling patients.

Common Pitfalls to Avoid

  1. Timing error: Patients must take linaclotide on an empty stomach, at least 30 minutes before meals. Taking with food may reduce efficacy 1.

  2. Underdosing in IBS-C: The 290 mcg dose is specifically approved for IBS-C, recognizing that CIC and IBS-C overlap in practice. Don't use the lower CIC dose for IBS-C patients with significant abdominal pain 1.

  3. Premature discontinuation: Counsel patients that diarrhea, if it occurs, is typically mild-moderate and may improve over time. Only 4-5% discontinue due to diarrhea 1.

  4. Pediatric use error: Never use in children under 2 years (BLACK BOX WARNING). For ages 6-17, only the 72 mcg dose is approved 2.

  5. Missing the indication: Linaclotide is particularly useful when patients have coexisting abdominal discomfort, pain, and bloating due to its effects on visceral hypersensitivity 1.

References

Related Questions

How should linaclotide (Linzess) be started, what are its contraindications, common adverse effects, and alternative treatment options?
Is Linzess (linaclotide) an appropriate treatment for irritable bowel syndrome with constipation (IBS‑C)?
What is the recommended dosing for Linzess (linaclotide) in adults with IBS‑C or chronic idiopathic constipation, and how should the dose be adjusted in renal impairment?
What are cheaper alternatives to linaclotide (Linzess) for treating irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation?
Can a primary care physician (PCP) prescribe Linzess (linaclotide)?
What types of exercises are safe after a transforaminal lumbar interbody fusion (TLIF) surgery?
What are the differential diagnoses for sinus bradycardia observed on a 12‑lead ECG?
In a 16-year-old adolescent with a two-month history of pervasive sadness, anhedonia, hypersomnia, fatigue, concentration difficulties, declining academic performance, and symptom worsening during menses, which diagnosis is most likely: major depressive disorder, persistent depressive disorder, or premenstrual dysphoric disorder?
What are the earliest radiographic findings of diffuse idiopathic skeletal hyperostosis (DISH) and where does it typically begin?
Can midodrine be used in a patient with cardiac disease who has symptomatic orthostatic hypotension?
What are the clinical features, diagnostic approach, management, and prevention strategies for Oya virus infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.